-
The first 10 months by the CDE priority review of 40 enterprises involving Hengrui, Junshi, stone medicine:
Time of Update: 2020-11-29
foreign enterprises, Roche 5 products were qualified for priority review, worthy of the global king of innovative drugs.
-
Dr. Du Ying of Reding Pharmaceuticals was awarded the first "Woman Leader of the Year Award" of the Baihua Association.
Time of Update: 2020-11-29
or pharmaceutical technology industry. under the leadership of Dr. Du Ying, Reding Pharmaceuticals has achieved rapid development and expansion, becoming one of the most valuable biotechnology companies in China. years, Dr. Du Ying has set
-
What are the characteristics of patent link systems in various countries?
Time of Update: 2020-11-29
In October 2017, the General Office of the CPC Central Committee and the General Office of the State Council issued the Opinions on Deepening the Reform of the Review and Approval System to Encourage Drug Medical Device Innovation (hereinafter
-
Effectively strengthen the quality control of the heart stent and effectively strengthen the quality control of the heart stent
Time of Update: 2020-11-29
After the crown bracket is included in the national centralized belt procurement, the quality problem also arouses concern at the same time that the price drops sharply. The State Drug Administration recently issued "on strengthening
-
4 enterprise hospitals are going to pack and reform!
Time of Update: 2020-11-29
enterprises to complete the medical institutions to help mixed reform, coking coal group's hospitals decided to break the ice mixed reform. Taiyuan Xishan Hospital Co., Ltd., Gudangshan West Mountain Hospital Co., Ltd., Shanxi Yanxi Mining Group
-
The Director's Interview . . Making the reform of the health care system "law-based"
Time of Update: 2020-11-29
In-depth promotion of the construction of medical insurance under the rule of law and deepening the reform of the medical security system are the firm direction and only way to achieve a higher level of medical security and promote high-quality
-
The National Health and Health Commission talks about comprehensive medical reform: "Internet plus" into the largest increment of reform and development
Time of Update: 2020-11-29
for comprehensive health reform in two batches. During the 13th Five-Year Plan period, the pilot provinces closely focused on the overall promotion of the construction of five basic medical and health systems and high-quality and efficient medical
-
Qiming Medical was approved as China's first second-generation artificial valve system
Time of Update: 2020-11-29
On November 16th Qiming Medical announced that its self-developed VenusA-Plus artificial aortic valve replacement system, the recyclable delivery system, had been approved for listing by the State Drug Administration.
-
The world's first off-the-skin injection of PD-L1 antibody Nwolly monoantigen injection was submitted to China for the new drug market application
Time of Update: 2020-11-29
Dee Pharmaceuticals Inc. (3D Pharmaceuticals Inc.) has reached a strategic partnership to restructure the humanized PD-L1 mono-domain antibody Nvolly monoantigen injection (research and development code: KN035) of the new drug market application (NDA
-
Song Ruixuan: Hengqin pharmaceutical industry innovation and development to go further
Time of Update: 2020-11-29
platforms for Chinese medicine products, developing the health industry, providing quality health care services, and promoting the overseas development of Chinese medicine. , China's pharmaceutical innovation should pay more attention
-
Drug Ming Juno will announce the best total remission rate of 75.9% for phase 2 clinical results of CAR-T therapy
Time of Update: 2020-11-29
On November 13th, The Drug Ming Juno announced that the results of a Phase 2 clinical trial for patients with recurring/recurring large B-cell lymphoma (LBCL) will be displayed as posters during the 62nd Annual Meeting of the American Society
-
Baiji Shenzhou plans to create an IPO
Time of Update: 2020-11-29
On November 15, 2020 (EST), the company's board of directors approved a preliminary proposal to issue RMB shares and put them on the board, baiji Shenzhou said in a statement. is expected to be completed in the first half of 2021
-
Xinda Bio announces clinical results for the treatment of anti-VEGF-anti-complementary dual-target drugs in the nAMDI stage
Time of Update: 2020-11-29
Phase I study of IBI302 is a single-arm, open, multi-center, single-dose incremental clinical study designed to assess the safety and tolerance of a single glass cavity injection of IBI302 in nAMD patients.
-
Tens of millions of dollars milestone payment Lilly co-developed RNAi gene therapy new drug application authorized
Time of Update: 2020-11-29
On November 16, RNA Interference (RNAi) gene therapy drug developer Dicerna Pharmaceuticals, Inc., announced that the FDA has now authorized a new drug application (IND) code-named LY3561774, the first clinical phase drug candidate for Dierna's partnership with Lilly.
-
How much impact does the new Biosecurity Act have on the biopharmaceutical industry?
Time of Update: 2020-11-29
laboratory, initially forming a national biosecurity laboratory system. At present, China has basically established a well-structured and well-established biosecurity prevention and control system with the Biosecurity Law as its core and composed
-
Gao's position exposure in the third quarter: 22 new companies, 10 biopharmaceutical companies
Time of Update: 2020-11-29
On November 17th, Beijing time, Gao announced its positions in U.S. stocks at the end of the third quarter of 2020. data show that Gao holds 89 companies in the U.S. stock market, with biomedicine, Internet and hard technology as the main
-
This month the EU CHMP recommended 5 new drugs on the market! Includes Roche Xofluza, Samsung Onbevzi
Time of Update: 2020-11-29
/>, CHMP issued a non-recommendation after a review, and three companies withdrew their marketing applications. new drug actively recommended: Phesgo (pertuzumab/trastuzumab) for the treatment of early and metastasis HER2-positive breast cancer. <br
-
The healthcare industry is ushering in a digital revolution
Time of Update: 2020-11-29
constantly combining to push the entire industry into a new landscape. the market is expanding According to statistics, during the epidemic, the National Health And Wellness Commission's management hospital Internet consultation volume increased 17
-
Under the normalization of collection and harvesting, domestic substitution has accelerated the transformation of multinational pharmaceutical companies
Time of Update: 2020-11-29
, Pfizer explained that the impact of Liputo and Live Hi did not enter the drug collection, Puqiang China's performance fell.
-
The State Council issued a document canceling the approval for the preparation and construction of pharmacies
Time of Update: 2020-11-29
The State Council issued a document to cancel the approval of the preparation and construction of pharmacies Recently, the General Office of the State Council issued the "National Deepening of the "Management Service" Reform and Optimization
